Navigation Links
Regeneron Reports First Quarter 2013 Financial and Operating Results
Date:5/3/2013

to evaluate the efficacy and safety of EYLEA in the treatment of diabetic macular edema (DME).  Both studies are fully enrolled.  In February 2013, Bayer HealthCare initiated another Phase 3 DME trial, VIVID EAST-DME, in Russia, China, and other Asian countries.
  • The VIBRANT study of EYLEA in macular edema following branch retinal vein occlusion (BRVO) is now fully enrolled.
  • ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion

  • The Company and Sanofi collaborate on the global development and commercialization of ZALTRAP, and share profits and losses from commercialization of ZALTRAP except for Japan, where the Company will receive a royalty on sales. 
  • In February 2013, the European Commission (EC) granted marketing authorization in the European Union for ZALTRAP concentrate for solution for infusion in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.  Marketing authorization applications for ZALTRAP are also currently under review by other regulatory agencies worldwide.
  • In the first quarter of 2013, Sanofi recorded worldwide net sales of ZALTRAP of $14 million.  
  • Monoclonal Antibodies

  • Regeneron has eleven fully human monoclonal antibodies based on the Company's VelocImmune® technology in clinical development, including six in collaboration with Sanofi.
  • ODYSSEY, a large, global Phase 3 program with alirocumab (REGN727), an antibody targeting PCSK9 to reduce LDL cholesterol, was initiated in June 2012 and is currently enrolling patients.  The Company expects to report initial results from a Phase 3 ODYSSEY trial in the second half of 2013.  Alirocumab is being developed in collaboration with Sanofi.
  • Positive proof of concept data from two Phase
    '/>"/>

  • SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
    2. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
    3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
    4. Regeneron Announces March 2012 Investor Conference Presentations
    5. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
    6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
    7. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
    8. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
    9. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
    10. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
    11. Cord Blood Banking Industry: 2013 Growth Opportunities Analysis in New Market Research Report at ReportsnReports.com
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
    (Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
    (Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
    (Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
    Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
    ... SOUTH SAN FRANCISCO, Calif., Aug. 27 Poniard,Pharmaceuticals, ... focused,on oncology, today announced that Jerry McMahon, Ph.D., ... in early September: The Thomas Weisel Partners ... p.m. Eastern time at the Four Seasons Hotel ...
    ... Aug. 27 Sanofi-aventis,U.S. launched today a new ... (oxaliplatin injection) for patients who have,adjuvant stage III ... to offer more convenience, efficiency and safety in ... had been,available in 50 mg and 100 mg ...
    ... Diabetes Meta-Database to Quantify Competitive Treatment Landscape and Accelerate ... ... MOUNTAIN VIEW, Calif., Aug. 27 Pharsight,Corporation (OTC Bulletin Board: ... clinical drug development, today,announced that it has licensed its public-source ...
    Cached Biology Technology:Poniard Pharmaceuticals Announces Participation in Upcoming Conferences 2New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 2New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 3New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 4New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 5New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 6New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 7Pharsight Achieves First License Sale for Public-Source Database 2Pharsight Achieves First License Sale for Public-Source Database 3
    (Date:7/10/2014)... teens living with a cardiac pacemaker, a low sense ... life, reports a study in the July ... official journal of the Society for Developmental and ... Lippincott Williams & Wilkins , a part of ... as a protective factor against lower health-related quality of ...
    (Date:7/10/2014)... used to control everyday household items such as washing ... for conservation, a new study has claimed., As part ... scientists and mathematicians, including those from the University of ... engineering, could be replicated in the natural world to ... ,integral control, - in essence a built-in feedback control ...
    (Date:7/10/2014)... Consuming a whole fresh avocado with either an orange-colored ... carotenoid (alpha- and beta-carotene) absorption and conversion of these ... to new research (1) published in The ... A is involved in reproductive health and growth promotion; ... has antioxidant properties. Provitamin A carotenoids, like alpha- and ...
    Breaking Biology News(10 mins):For children with pacemakers, 'self-competence' affects quality of life 2Feedback control could be key to robust conservation management 2New research: Fresh avocado enhances absorption of essential nutrients for healthy living 2
    ... Kolls, Professor and Chairman of Genetics at the LSU Health ... a $2.1 million grant over five years by the National ... Health to further his work on a discovery that plays ... Bacterial pneumonia is an important clinical problem and defense mechanisms ...
    ... a first-of-its-kind cloth that releases nitric oxide gas an ... a wrap to help preserve organs harvested for transplantation. The ... bi-weekly journal. Kenneth Balkus and Harvey Liu note in ... flow and regulates a range of other body functions. Scientists ...
    ... drugs are embracing new tactics to deal with an ... far from being won. That,s the focus of an ... Engineering News (C&EN) , ACS, weekly newsmagazine. Counterfeiting ploys ... to identify their products as genuine. C&EN Associate ...
    Cached Biology News:LSUHSC awarded multi-million dollar grant to reduce pneumonia 2
    ... ESGRO Complete Derivation Kit is ... ES cells from delayed blastocysts in ... Clonal ... Delayed Blastocyst Incubation Medium Trypsin ...
    Template and primers for preparation of internal control spots...
    Reusble. Uses in conjunction with the Apoptotic Cell Isolation Kit....
    ANTI K. AEROGENES...
    Biology Products: